Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

Journal of Clinical Investigation

Volumn 126, Issue 5, 2016, Pages 1834-1856

  Zhang, Gao ^a   Frederick, Dennie T ^b   Wu, Lawrence ^a   Wei, Zhi ^c   Krepler, Clemens ^a   Srinivasan, Satish ^d   Chae, Young Chan ^a   Xu, Xiaowei ^e   Choi, Harry ^a   Dimwamwa, Elaida ^a   Ope, Omotayo ^a   Shannan, Batool ^a   Basu, Devraj ^f,g   Zhang, Dongmei ^f   Guha, Manti ^d   Xiao, Min ^a   Randell, Sergio ^a   Sproesser, Katrin ^a   Xu, Wei ^e   Liu, Jephrey ^e   Karakousis, Giorgos C ^e   Schuchter, Lynn M ^e   Gangadhar, Tara C ^e   Amaravadi, Ravi K ^e   Gu, Mengnan ^c   Xu, Caiyue ^a   Ghosh, Abheek ^a   Xu, Weiting ^c   Tian, Tian ^c   Zhang, Jie ^c   Zha, Shijie ^c   Liu, Qin ^a   Brafford, Patricia ^a   Weeraratna, Ashani ^a   Davies, Michael A ^h   Wargo, Jennifer A ^h   Avadhani, Narayan G ^d   Lu, Yiling ^h   Mills, Gordon B ^h   Altieri, Dario C ^a   Flaherty, Keith T ^b,i   Herlyn, Meenhard ^a   more..

^a WISTAR INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c University Heights   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BINIMETINIB; ENCORAFENIB; GAMITRINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PROTEIN TRAP1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; GAMITRINIB-G4; GUANIDINE DERIVATIVE; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; TFAM PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRAP1 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOENERGY; CANCER INHIBITION; CELL STRESS; CONTROLLED STUDY; DNA CONTENT; DRUG TARGETING; GENE REPLICATION; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL LINE; MITOCHONDRIAL BIOGENESIS; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN FOLDING; REGULATORY MECHANISM; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEMALE; GENETICS; MALE; METABOLISM; MITOCHONDRIAL DYNAMICS; MITOCHONDRION; PATHOLOGY;

ANIMALS; DNA-BINDING PROTEINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GUANIDINES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MELANOMA; MICE; MITOCHONDRIA; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL PROTEINS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; TRANSCRIPTION FACTORS;

EID: 84988531155     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82661     Document Type: Article

References (38)

1. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park). 2009;23(6):488-496.
2. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
3. McArthur GA, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323-332.
4. Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
5. Bollag G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596-599.
6. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
7. Flaherty KT, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
8. Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703.
9. Shi H, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80-93.
10. Whittaker SR, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013;3(3):350-362.
11. Kaplon J, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature. 2013;498(7452):109-112.
12. Haq R, et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A. 2013;110(11):4321-4326.
13. Haq R, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell. 2013;23(3):302-315.
14. Abel EV, et al. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest. 2013;123(5):2155-2168.
15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
16. Roesch A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141(4):583-594.
17. Roesch A, et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID-1B(high) cells. Cancer Cell. 2013;23(6):811-825.
18. Vazquez F, et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell. 2013;23(3):287-301.
19. Alvarez-Calderon F, et al. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clin Cancer Res. 2015;21(6):1360-1372.
20. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 2004;18(4):357-368.
21. Gleyzer N, Vercauteren K, Scarpulla RC. Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol Cell Biol. 2005;25(4):1354-1366.
22. Di Re M, et al. The accessory subunit of mitochondrial DNA polymerase gamma determines the DNA content of mitochondrial nucleoids in human cultured cells. Nucleic Acids Res. 2009;37(17):5701-5713.
23. Supale S, et al. Loss of prohibitin induces mitochondrial damages altering β-cell function and survival and is responsible for gradual diabetes development. Diabetes. 2013;62(10):3488-3499.
24. Shirendeb U, et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet. 2011;20(7):1438-1455.
25. Barretina J, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607.
26. Kabbarah O, et al. Integrative genome comparison of primary and metastatic melanomas. PLoS One. 2010;5(5):e10770.
27. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681-1696.
28. Litvin O, et al. Interferon α/β enhances the cytotoxic response of MEK inhibition in melanoma. Mol Cell. 2015;57(5):784-796.
29. Kokoszka JE, Coskun P, Esposito LA, Wallace DC. Increased mitochondrial oxidative stress in the Sod2 (+/-) mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. Proc Natl Acad Sci U S A. 2001;98(5):2278-2283.
30. Viale A, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514(7524):628-632.
31. Cheng MY, Hartl FU, Horwich AL. The mitochondrial chaperonin hsp60 is required for its own assembly. Nature. 1990;348(6300):455-458.
32. Skrtic M, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011;20(5):674-688.
33. Ekstrand MI, et al. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum Mol Genet. 2004;13(9):935-944.
34. Kang BH, et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest. 2009;119(3):454-464.
35. Chae YC, et al. Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun. 2013;4:2139.
36. Chae YC, et al. Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell. 2012;22(3):331-344.
37. Gopal YN, et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1alpha and oxidative phosphorylation in melanoma. Cancer Res. 2014;74(23):7037-7047.
38. Lagadinou ED, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329-341.